ZAI LAB LIMITED Debt Securities, Available-for-sale, Allowance for Credit Loss
ZAI LAB LIMITED (ZLAB) had Debt Securities, Available-for-sale, Allowance for Credit Loss of $0 as of 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Notes
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss · last filed 2021-11-09
- 2021-09-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2020-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss |
|---|---|
| 2021-09-30 | $0.00 10-Q · filed 2021-11-09 |
| 2020-12-31 | $0.00 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |